Clinical trials
Recurrent Acute Myeloid Leukemia clinical trials
Below are recruiting recurrent acute myeloid leukemia clinical trials, each written for real people, not researchers. We’re tracking 110 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04167696RecruitingPhase 1
Dose-finding drug study for AML or MDS after standard options fail
This Phase 1 trial tests CYAD-02 to find the safest and recommended dose for people with AML or MDS that has returned or did not respond to prior treatment. It may help if you have limited treatment options, but participation also requires meeting specific heart, lung, and lab safety requirements.
Jacksonville, FloridaAges 18 years+ - NCT06329999Recruiting
CMGV for recurrent AML and high-risk MDS
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06418776RecruitingPhase 3
Comparing treatments for AML that returns or doesn't respond
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
MoscowAges 18 years+ - NCT04905810RecruitingPhase 2
Azacitidine or decitabine plus venetoclax for AML after prior failure
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Clovis, CaliforniaAges 18 years+ - NCT06536959RecruitingPhase 2
VA plus PD-1 inhibitor for relapsed AML and high-risk MDS
This trial tests a combination of two drugs—a chemotherapy-like agent called VA and a PD-1 inhibitor (which helps your immune system fight cancer)—for people with AML or high-risk MDS that has not responded to or returned after initial treatment. The goal is to see if this combination can work better than standard treatments alone.
Beijing, Beijing MunicipalityAges 18–70 - NCT06626893Recruiting
Leukemia study using advanced tests to find targeted treatment
This study uses advanced tests (genetics and other 'omics' methods) to better understand your leukemia and find a treatment that targets its specific features. It may help if standard treatments haven't worked or stopped working.
Meldola, Forlì-CesenaAges 18 years+ - NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT06420063RecruitingPhase 1/Phase 2
Two-step CAR-T therapy for AML with CD33/CD123
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
Beijing, Beijing MunicipalityAges 6–90 - NCT07616921Recruiting
Home Exercise Program for Heart Health During Leukemia Transplant
This study tests whether doing gentle exercise at home can help protect your heart during stem cell transplant treatment for acute myeloid leukemia (a type of blood cancer). You'll use a smartphone app to guide daily workouts designed to be safe and manageable during your treatment.
Seattle, WashingtonAges 18 years+ - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT06741722RecruitingPhase 2
Study of mitoxantrone liposome combo for relapsed or refractory AML
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
BeijingAges 18–75 - NCT06762132RecruitingEarly Phase 1
CD33 car-t cell therapy for returning or hard-to-treat aml
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
Hangzhou, ZhejiangAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Coeur d'Alene, IdahoAges 60 years+ - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT07347418RecruitingPhase 1
CD64 CAR T cell therapy for relapsed or refractory AML
This trial tests a type of immunotherapy called CAR T cells that target a protein called CD64 on leukemia cells. It is for adults with AML that has come back or not responded to treatment, including venetoclax.
Aurora, ColoradoAges 18 years+ - NCT07304011RecruitingPhase 2
Olutasidenib and azacitidine for IDH1-mutated AML after venetoclax
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
Orange, CaliforniaAges 18 years+ - NCT07263906RecruitingPhase 1
LILRA6 car-t therapy for resistant or relapsed aml
This early-phase trial tests a new cell therapy (CAR-T) that targets a protein called LILRA6 on leukemia cells. It's designed for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07255872RecruitingPhase 2/Phase 3
BL-M11D1 plus chemo for newly diagnosed AML
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06118788RecruitingPhase 1/Phase 2
BG1805 for relapsed or refractory acute myeloid leukemia
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
Guangzhou, GuangdongAges 18–70 - NCT06869265RecruitingPhase 2
Thiotepa added to standard chemo before a stem cell transplant for older adults with high-risk AML
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
Beijing, Beijing MunicipalityAges 55–70 - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07022678RecruitingPhase 3
Xylitol dental wipes to reduce infection risk in childhood leukemia
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Birmingham, AlabamaAges 1–25 - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Recurrent Acute Myeloid Leukemia trials by city
Studies with a site in or near these metro areas.
Recurrent Acute Myeloid Leukemia trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for recurrent acute myeloid leukemia?
- Yes. Clin2 currently lists 110 recruiting recurrent acute myeloid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent acute myeloid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.